Detalhe da pesquisa
1.
Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity.
Molecules
; 28(19)2023 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37836790
2.
Small Molecule Degraders of Protein Tyrosine Phosphatase 1B and T-Cell Protein Tyrosine Phosphatase for Cancer Immunotherapy.
Angew Chem Int Ed Engl
; 62(22): e202303818, 2023 05 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36973833
3.
Development of Novel Phosphonodifluoromethyl-Containing Phosphotyrosine Mimetics and a First-In-Class, Potent, Selective, and Bioavailable Inhibitor of Human CDC14 Phosphatases.
J Med Chem
; 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38768084
4.
Discovery of a selective TC-PTP degrader for cancer immunotherapy.
Chem Sci
; 14(44): 12606-12614, 2023 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38020389
5.
PTPN22: structure, function, and developments in inhibitor discovery with applications for immunotherapy.
Expert Opin Drug Discov
; 17(8): 825-837, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35637605
6.
Discovery of Decamidine as a New and Potent PRMT1 Inhibitor.
Medchemcomm
; 8(2): 440-444, 2017 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28649316